We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
The Human Animal Infections and Risk Surveillance (HAIRS) group identifies and assesses emerging infection risks to human health.
Updates on new or emerging infectious disease events that could affect UK public health.
Sections (24.01 to 24.13) last updated: September 2017.
Information for EU citizens and their families applying to the EU Settlement Scheme.
Employment Tribunal decision.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (6 March 2024) approved the medicine piflufolastat (18F) (Pylclari) as a diagnostic tool for people with suspected or known prostate cancer.
First published during the 2019 to 2022 Johnson Conservative government
The community diagnostic centre (CDC) programme is largest central cash investment in MRI and CT scanning capacity in the history of the NHS.
First published during the 2022 to 2024 Sunak Conservative government
Guidance for those affected by changes to UK immigration and borders due to coronavirus.
Approved security scanners for screening people at airports.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).